Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
FCMR Biologics Sequence Review Report 2026: Immunoglobulin mu Fc receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCMR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FRS3 Biologics Sequence Review Report 2026: Fibroblast growth factor receptor substrate 3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FRS3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GPA33 Biologics Sequence Review Report 2026: Cell surface A33 antigen Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of GPA33 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCAR Biologics Sequence Review Report 2026: Immunoglobulin alpha Fc receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCAR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCER2 Biologics Sequence Review Report 2026: Low affinity immunoglobulin epsilon Fc receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCER2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCGR1BP Biologics Sequence Review Report 2026: Putative high affinity immunoglobulin gamma Fc receptor IB Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCGR1BP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCER1A Biologics Sequence Review Report 2026: High affinity immunoglobulin epsilon receptor subunit alpha Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCER1A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FAS Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 6 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FAS protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCAMR Biologics Sequence Review Report 2026: High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FCAMR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FASLG Biologics Sequence Review Report 2026: Tumor necrosis factor ligand superfamily member 6 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of FASLG protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EDAR Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member EDAR Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of EDAR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EDA2R Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 27 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of EDA2R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.